Heart
| Zeile 2: | Zeile 2: | ||
{{tp|p=32310612|t=2020. Cardiac Manifestations Of Coronavirus (COVID-19)|pdf=|usr=}} | {{tp|p=32310612|t=2020. Cardiac Manifestations Of Coronavirus (COVID-19)|pdf=|usr=}} | ||
{{tp|p=32281055|t=ä. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19 |pdf=|usr=}} | {{tp|p=32281055|t=ä. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19 |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32317203|t=ä. Cardiovascular complications in COVID-19 |pdf=|usr=}} | {{tp|p=32317203|t=ä. Cardiovascular complications in COVID-19 |pdf=|usr=}} | ||
{{tp|p=32251498|t=ä. Hypertension and COVID-19 |pdf=|usr=}} | {{tp|p=32251498|t=ä. Hypertension and COVID-19 |pdf=|usr=}} | ||
| Zeile 10: | Zeile 10: | ||
{{tp|p=32252591|t=2020. COVID-19 and the Heart |pdf=|usr=}} | {{tp|p=32252591|t=2020. COVID-19 and the Heart |pdf=|usr=}} | ||
{{tp|p=32363334|t=ä. Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) |pdf=|usr=}} | {{tp|p=32363334|t=ä. Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32331780|t=ä. COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging |pdf=|usr=}} | {{tp|p=32331780|t=ä. COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging |pdf=|usr=}} | ||
{{tp|p=32318865|t=2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response |pdf=|usr=}} | {{tp|p=32318865|t=2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response |pdf=|usr=}} | ||
{{tp|p=32247212|t=2020. Cardiovascular disease and COVID-19 |pdf=|usr=}} | {{tp|p=32247212|t=2020. Cardiovascular disease and COVID-19 |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32196087|t=ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19?|pdf=|usr=}} | {{tp|p=32196087|t=ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19?|pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32285920|t=ä. Transient complete heart block in a patient with critical COVID-19 |pdf=|usr=}} | {{tp|p=32285920|t=ä. Transient complete heart block in a patient with critical COVID-19 |pdf=|usr=}} | ||
{{tp|p=32285915|t=ä. Typical takotsubo syndrome triggered by SARS-CoV-2 infection |pdf=|usr=}} | {{tp|p=32285915|t=ä. Typical takotsubo syndrome triggered by SARS-CoV-2 infection |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32359887|t=ä. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade |pdf=|usr=}} | {{tp|p=32359887|t=ä. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade |pdf=|usr=}} | ||
| Zeile 29: | Zeile 29: | ||
{{tp|p=32373465|t=ä. Syncope as the presenting symptom of COVID-19 infection |pdf=|usr=}} | {{tp|p=32373465|t=ä. Syncope as the presenting symptom of COVID-19 infection |pdf=|usr=}} | ||
{{tp|p=32315757|t=ä. Current data on the cardiovascular effects of the COVID-19 |pdf=|usr=}} | {{tp|p=32315757|t=ä. Current data on the cardiovascular effects of the COVID-19 |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32333026|t=ä. Arrhythmias and sudden cardiac death in the COVID-19 pandemic |pdf=|usr=}} | {{tp|p=32333026|t=ä. Arrhythmias and sudden cardiac death in the COVID-19 pandemic |pdf=|usr=}} | ||
{{tp|p=32322935|t=ä. SARS-CoV-2 as potential cause of cardiac inflammation and heart failure Is it the virus, hyperinflammation, or MODS?|pdf=|usr=}} | {{tp|p=32322935|t=ä. SARS-CoV-2 as potential cause of cardiac inflammation and heart failure Is it the virus, hyperinflammation, or MODS?|pdf=|usr=}} | ||
| Zeile 35: | Zeile 35: | ||
{{tp|p=32355222|t=ä. A novel COVID-19 and its effects on cardiovascular disease |pdf=|usr=}} | {{tp|p=32355222|t=ä. A novel COVID-19 and its effects on cardiovascular disease |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32360773|t=ä. May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?|pdf=|usr=}} | {{tp|p=32360773|t=ä. May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?|pdf=|usr=}} | ||
{{tp|p=32276773|t=ä. Commentary: What is the relationship between Covid-19 and cardiovascular disease?|pdf=|usr=}} | {{tp|p=32276773|t=ä. Commentary: What is the relationship between Covid-19 and cardiovascular disease?|pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32299753|t=ä. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society |pdf=|usr=}} | {{tp|p=32299753|t=ä. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32370558|t=2020. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection |pdf=|usr=}} | {{tp|p=32370558|t=2020. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection |pdf=|usr=}} | ||
{{tp|p=32360703|t=ä. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications |pdf=|usr=}} | {{tp|p=32360703|t=ä. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications |pdf=|usr=}} | ||
| Zeile 50: | Zeile 50: | ||
{{tp|p=C7151324|t=ä. The Heart in COVID19: Primary Target or Secondary Bystander?|pdf=|usr=}} | {{tp|p=C7151324|t=ä. The Heart in COVID19: Primary Target or Secondary Bystander?|pdf=|usr=}} | ||
{{tp|p=32368756|t=ä. HEART BRAKE-An unusual cardiac manifestation of Coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32368756|t=ä. HEART BRAKE-An unusual cardiac manifestation of Coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32310242|t=ä. The Known into the Unknown: Brugada syndrome and COVID-19 |pdf=|usr=}} | {{tp|p=32310242|t=ä. The Known into the Unknown: Brugada syndrome and COVID-19 |pdf=|usr=}} | ||
{{tp|p=32309815|t=ä. Transient Brugada-like ECG pattern in a patient with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32309815|t=ä. Transient Brugada-like ECG pattern in a patient with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
{{tp|p=32265149|t=ä. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV |pdf=|usr=}} | {{tp|p=32265149|t=ä. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV |pdf=|usr=}} | ||
{{tp|p=32360242|t=2020. COVID-19 Illness and Heart Failure: A Missing Link?|pdf=|usr=}} | {{tp|p=32360242|t=2020. COVID-19 Illness and Heart Failure: A Missing Link?|pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}} | {{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32319272|t=2020. COVID-19 and cardiovascular disorder |pdf=|usr=}} | {{tp|p=32319272|t=2020. COVID-19 and cardiovascular disorder |pdf=|usr=}} | ||
{{tp|p=32340429|t=2020. The role of natriuretic peptide estimation in severe COVID-19 |pdf=|usr=}} | {{tp|p=32340429|t=2020. The role of natriuretic peptide estimation in severe COVID-19 |pdf=|usr=}} | ||
| Zeile 69: | Zeile 66: | ||
{{tp|p=32139904|t=ä. COVID-19 and the cardiovascular system |pdf=|usr=}} | {{tp|p=32139904|t=ä. COVID-19 and the cardiovascular system |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32353374|t=ä. Towards precision management of cardiovascular patients with COVID-19 to reduce mortality |pdf=|usr=}} | {{tp|p=32353374|t=ä. Towards precision management of cardiovascular patients with COVID-19 to reduce mortality |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32293449|t=2020. Prognostic value of NT-proBNP in patients with severe COVID-19 |pdf=|usr=}} | {{tp|p=32293449|t=2020. Prognostic value of NT-proBNP in patients with severe COVID-19 |pdf=|usr=}} | ||
{{tp|p=32372844|t=ä. COVID-19 y tratamiento guiado con tests de diagnostico bioquemicos y moleculares para reducir el dao cardiaco y la cardiotoxicidad |pdf=|usr=}} | {{tp|p=32372844|t=ä. COVID-19 y tratamiento guiado con tests de diagnostico bioquemicos y moleculares para reducir el dao cardiaco y la cardiotoxicidad |pdf=|usr=}} | ||
{{tp|p=32355394|t=ä. COVID-19 y shock cardiogonico: diferentes formas de presentacion cardiovascular con alta mortalidad |pdf=|usr=}} | {{tp|p=32355394|t=ä. COVID-19 y shock cardiogonico: diferentes formas de presentacion cardiovascular con alta mortalidad |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32267110|t=2020. COVID-19 et maladies cardiovasculaires |pdf=|usr=}} | {{tp|p=32267110|t=2020. COVID-19 et maladies cardiovasculaires |pdf=|usr=}} | ||
{{tp|p=32227794|t=2020. At the heart of the COVID-19 outbreak: early cardiac implications and mitigating strategies |pdf=|usr=}} | {{tp|p=32227794|t=2020. At the heart of the COVID-19 outbreak: early cardiac implications and mitigating strategies |pdf=|usr=}} | ||
{{tp|p=32312365|t=2020. Research advances in cardiovascular system damage caused by SARS-CoV-2 in children |pdf=|usr=}} | {{tp|p=32312365|t=2020. Research advances in cardiovascular system damage caused by SARS-CoV-2 in children |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
{{tp|p=32243205|t=2020. The Variety of Cardiovascular Presentations of COVID-19 |pdf=|usr=}} | {{tp|p=32243205|t=2020. The Variety of Cardiovascular Presentations of COVID-19 |pdf=|usr=}} | ||
{{tp|p=32298134|t=2020. Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings |pdf=|usr=}} | {{tp|p=32298134|t=2020. Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32286863|t=2020. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap!|pdf=|usr=}} | {{tp|p=32286863|t=2020. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap!|pdf=|usr=}} | ||
{{ttp|p=32354733|t=2020. SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know |pdf=|usr=}} | {{ttp|p=32354733|t=2020. SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| + | |||
{{tp|p=32282502|t=ä. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32282502|t=ä. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
{{tp|p=32306491|t=2020. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review |pdf=|usr=}} | {{tp|p=32306491|t=2020. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review |pdf=|usr=}} | ||
{{tp|p=32270559|t=2020. Cardiac and arrhythmic complications in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32270559|t=2020. Cardiac and arrhythmic complications in patients with COVID-19 |pdf=|usr=}} | ||
| − | |||
| − | |||
{{tp|p=32219357|t=2020. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32219357|t=2020. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
{{tp|p=32219363|t=2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review |pdf=|usr=}} | {{tp|p=32219363|t=2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32356626|t=ä. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 |pdf=|usr=}} | {{tp|p=32356626|t=ä. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32129583|t=2020. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics |pdf=|usr=}} | {{tp|p=32129583|t=2020. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics |pdf=|usr=}} | ||
{{tp|p=32118392|t=2020. Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations |pdf=|usr=}} | {{tp|p=32118392|t=2020. Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32347088|t=2020. Effects of novel coronavirus therapeutic drugs on cardiovascular system |pdf=|usr=}} | {{tp|p=32347088|t=2020. Effects of novel coronavirus therapeutic drugs on cardiovascular system |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=C7196397|t=ä. A review of cardiac manifestations and predictors of outcome in patients with COVID ? 19 |pdf=|usr=}} | {{tp|p=C7196397|t=ä. A review of cardiac manifestations and predictors of outcome in patients with COVID ? 19 |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32423554|t=2020. Coronavirus disease 2019 and the cardiovascular system: Impacts and implications |pdf=|usr=}} | {{tp|p=32423554|t=2020. Coronavirus disease 2019 and the cardiovascular system: Impacts and implications |pdf=|usr=}} | ||
{{tp|p=32451271|t=ä. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications |pdf=|usr=}} | {{tp|p=32451271|t=ä. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications |pdf=|usr=}} | ||
| Zeile 126: | Zeile 112: | ||
{{tp|p=32349897|t=2020. Cardiovascular Consequences and Considerations of Coronavirus Infection ? Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis |pdf=|usr=}} | {{tp|p=32349897|t=2020. Cardiovascular Consequences and Considerations of Coronavirus Infection ? Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32297133|t=ä. Toward understanding the 2019 Coronavirus and its impact on the heart |pdf=|usr=}} | {{tp|p=32297133|t=ä. Toward understanding the 2019 Coronavirus and its impact on the heart |pdf=|usr=}} | ||
{{tp|p=32292848|t=2020. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies |pdf=|usr=}} | {{tp|p=32292848|t=2020. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies |pdf=|usr=}} | ||
| Zeile 136: | Zeile 121: | ||
{{tp|p=C7184000|t=ä. COVID-19 and cardiogenic shock Different cardiovascular presentations with high mortality |pdf=|usr=}} | {{tp|p=C7184000|t=ä. COVID-19 and cardiogenic shock Different cardiovascular presentations with high mortality |pdf=|usr=}} | ||
{{tp|p=32448590|t=ä. Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2 Mediated COVID-19 |pdf=|usr=}} | {{tp|p=32448590|t=ä. Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2 Mediated COVID-19 |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32456948|t=ä. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19 |pdf=|usr=}} | {{tp|p=32456948|t=ä. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19 |pdf=|usr=}} | ||
{{tp|p=32423664|t=ä. A close-up on COVID-19 and cardiovascular diseases |pdf=|usr=}} | {{tp|p=32423664|t=ä. A close-up on COVID-19 and cardiovascular diseases |pdf=|usr=}} | ||
Version vom 11. Juni 2020, 13:18 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
32310612 2020. Cardiac Manifestations Of Coronavirus (COVID-19)
32281055 ä. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
32317203 ä. Cardiovascular complications in COVID-19
32251498 ä. Hypertension and COVID-19
32209811 2020. Angiotensin II for the Treatment of COVID-19?Related Vasodilatory Shock
32303363 ä. ...impact sur le systeme cardiovasculaire...
32344395 2020. The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection
32252591 2020. COVID-19 and the Heart
32363334 ä. Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)
32331780 ä. COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging
32318865 2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
32247212 2020. Cardiovascular disease and COVID-19
32196087 ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19?
32285920 ä. Transient complete heart block in a patient with critical COVID-19
32285915 ä. Typical takotsubo syndrome triggered by SARS-CoV-2 infection
32359887 ä. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade
32354800 2020. Cardiovascular manifestations and treatment considerations in covid-19
32305329 2020. Cardiovascular and Logistic Issues Associated With COVID-19 Pandemic
32373465 ä. Syncope as the presenting symptom of COVID-19 infection
32315757 ä. Current data on the cardiovascular effects of the COVID-19
32333026 ä. Arrhythmias and sudden cardiac death in the COVID-19 pandemic
32322935 ä. SARS-CoV-2 as potential cause of cardiac inflammation and heart failure Is it the virus, hyperinflammation, or MODS?
32355222 ä. A novel COVID-19 and its effects on cardiovascular disease
32360773 ä. May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?
32276773 ä. Commentary: What is the relationship between Covid-19 and cardiovascular disease?
32299753 ä. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society
32370558 2020. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection
32360703 ä. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications
32339565 ä. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
32289321 ä. Cardiovascular molecular mechanisms of disease with COVID-19
C7151324 ä. The Heart in COVID19: Primary Target or Secondary Bystander?
32368756 ä. HEART BRAKE-An unusual cardiac manifestation of Coronavirus disease 2019 (COVID-19)
32310242 ä. The Known into the Unknown: Brugada syndrome and COVID-19
32309815 ä. Transient Brugada-like ECG pattern in a patient with Coronavirus Disease 2019 (COVID-19)
32265149 ä. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV
32360242 2020. COVID-19 Illness and Heart Failure: A Missing Link?
32334650 ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes
32319272 2020. COVID-19 and cardiovascular disorder
32340429 2020. The role of natriuretic peptide estimation in severe COVID-19
32348640 ä. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy
32139904 ä. COVID-19 and the cardiovascular system
32353374 ä. Towards precision management of cardiovascular patients with COVID-19 to reduce mortality
32293449 2020. Prognostic value of NT-proBNP in patients with severe COVID-19
32372844 ä. COVID-19 y tratamiento guiado con tests de diagnostico bioquemicos y moleculares para reducir el dao cardiaco y la cardiotoxicidad
32355394 ä. COVID-19 y shock cardiogonico: diferentes formas de presentacion cardiovascular con alta mortalidad
32267110 2020. COVID-19 et maladies cardiovasculaires
32227794 2020. At the heart of the COVID-19 outbreak: early cardiac implications and mitigating strategies
32312365 2020. Research advances in cardiovascular system damage caused by SARS-CoV-2 in children
32243205 2020. The Variety of Cardiovascular Presentations of COVID-19
32298134 2020. Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings
32286863 2020. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap!
| 32354733 2020. SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know |
32282502 ä. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19)
32306491 2020. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review
32270559 2020. Cardiac and arrhythmic complications in patients with COVID-19
32219357 2020. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)
32219363 2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review
32356626 ä. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
32129583 2020. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics
32118392 2020. Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations
32347088 2020. Effects of novel coronavirus therapeutic drugs on cardiovascular system
C7196397 ä. A review of cardiac manifestations and predictors of outcome in patients with COVID ? 19
32423554 2020. Coronavirus disease 2019 and the cardiovascular system: Impacts and implications
32451271 ä. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications
32413697 2020. Wide complex tachycardia in a COVID-19 patient: What is the mechanism?
32349897 2020. Cardiovascular Consequences and Considerations of Coronavirus Infection ? Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis
32297133 ä. Toward understanding the 2019 Coronavirus and its impact on the heart
32292848 2020. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies
32292847 2020. The Heart in COVID-19: Primary Target or Secondary Bystander?
C7195441 ä. Prognostic Value of Right Ventricular Longitudinal Strain in Patients with COVID-19
C7142671 ä. Spontaneous Coronary Artery Dissection in a Patient with COVID-19
| 32386565 2020. Hyperinflammatory shock in children during COVID-19 pandemic |
C7184000 ä. COVID-19 and cardiogenic shock Different cardiovascular presentations with high mortality
32448590 ä. Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2 Mediated COVID-19
32456948 ä. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19
32423664 ä. A close-up on COVID-19 and cardiovascular diseases
